4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity (MODE)

The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity (MODE)

Study Description
Brief Summary:

Canadian guidelines recommend that women with a pre-pregnancy body mass index (BMI) at or above 40 kg/m2 deliver by their due date. When delivery is planned prior to spontaneous labour, there are two options: planned induction of labour or pre-labour Caesarean (C-section). However, it is not yet clear whether induction of labour or planned pre-labour C-section is the best option for this population.

The MODE Trial aims to assess the feasibility of conducting a larger-scale trial of planned mode of delivery in first time mothers who have a BMI >=40kg/m2, and obtain preliminary data on health outcomes for moms and babies following delivery by either planned C-section or induction of labour.


Condition or disease Intervention/treatment Phase
Obesity Complicating Childbirth Obesity Labor Onset and Length Abnormalities Pregnancy, High Risk Cesarean Section Complications Procedure: Caesarean section Procedure: Induction of Labour Not Applicable

Detailed Description:

Women with obesity have a decreased likelihood of achieving vaginal delivery. According to the Centre for Maternal and Child Enquiries, the chance of spontaneous vaginal delivery in women with a BMI ≥35kg/m2 is 55%, while the chance is 36.7% in women with a BMI ≥40.0kg/m2. This number includes women who go into labour spontaneously, in which, the odds of a vaginal delivery are highest. The rate of failure to induce labour approaches 80% with increased complications and morbidity including abnormal fetal heart rate monitoring, labour dystocia, emergency C-section, and fetal macrosomia. It has been proposed that some women may benefit from a planned Caesarean section delivery. However, Caesarean sections are also not straightforward in women with obesity, and come with significant risks of short- and long-term morbidity for mother and baby, including prolonged operative times, higher volumes of blood loss and infection rates and higher rates of NICU admission.

Given that there are many considerations when deciding how to best deliver a woman with obesity, it is not surprising that there is a high degree of clinical equipoise. In reality, the decision is made jointly between the patient and her care provider, often guided by overall instinct and local resource availability.

Studies to date have been retrospective in nature. There is a significant need for prospective study of the outcomes and experiences of planned induction of labour and planned Caesarean section in women with obesity to allow evidence-based counselling and decision-making.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Brewin partially randomized control trial, patient preference trial. In this design, each eligible patient is asked for her preference for mode of delivery. Patients with a preference are given their delivery mode of choice. If a patient does not have a preference, randomization takes place. Advantages to this design include the fact that preferences are taken into account in care allocation and that almost all those who are eligible enter the study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The MODE Trial: A Pilot Trial Investigating Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : August 31, 2021
Arms and Interventions
Arm Intervention/treatment
Active Comparator: Randomized Caesarean section
Randomized to planned pre-labour Caesarean section
Procedure: Caesarean section
Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
Other Names:
  • C-section
  • Cesarean

Active Comparator: Randomized Induction of Labour
Randomized to planned induction of labour
Procedure: Induction of Labour
Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.

Active Comparator: Preference Caesarean section
Preference for planned pre-labour Caesarean section
Procedure: Caesarean section
Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
Other Names:
  • C-section
  • Cesarean

Active Comparator: Preference Induction of Labour
Preference for planned Induction of Labour
Procedure: Induction of Labour
Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.

Outcome Measures
Primary Outcome Measures :
  1. Feasibility of conducting a larger-scale trial (eligibility criteria) [ Time Frame: 18 months ]
    Appropriateness of eligibility criteria, measured by the reasons for exclusion of screened patients

  2. Feasibility of conducting a larger-scale trial (recruitment rate) [ Time Frame: 18 months ]
    Eligibility and recruitment rate, measured by the proportion of patients who are eligible and recruited into the trial

  3. Feasibility of conducting a larger-scale trial (randomization) [ Time Frame: 18 months ]
    Appropriateness of randomization, measured by the proportion of trial participants who consent to randomization


Secondary Outcome Measures :
  1. Maternal morbidity and mortality [ Time Frame: Pregnancy to 6 week postpartum ]
    Rates of: maternal death, admission to ICU, intrapartum Caesarean section, postpartum hemorrhage, postpartum wound infection, endometritis, venous thromboembolism (VTE), hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), indication for Caesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incision extensions during Caesarean section, chorioamnionitis, third or fourth degree perineal lacerations, induction agents, pain medication use during induction, labour, Caesarean section and postpartum.

  2. Fetal and neonatal morbidity and mortality [ Time Frame: Pregnancy to 6 week postpartum ]
    Rates of: stillbirth, neonatal death, gestational age at birth, birthweight, need for respiratory support within 72 hours of birth, duration of respiratory support, 5 minute Apgar <7, hypoxic-ischemic encephalopathy, seizure, infection (confirmed sepsis or pneumonia), meconium aspiration syndrome, birth trauma (bone fracture, neurologic injury or retinal hemorrhage), cephalohematoma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support, breastfeeding rates, hypoglycemia requiring intravenous treatment, jaundice requiring treatment, need for transfusion.

  3. Length of hospital stay [ Time Frame: Start of induction to delivery; admission to delivery; and delivery until discharge, assessed up until 6-weeks postpartum ]
    Length of hospital stay (in minutes) for both mom and baby

  4. Hospital readmission rates [ Time Frame: Delivery to 6-weeks postpartum ]
    The proportion of mothers and/or infants re-admitted to the hospital

  5. Techniques for induction of labour [ Time Frame: Admission to hospital until delivery, assessed up to 7 days from hospital admission. ]
    What method was used for induction

  6. Maternal satisfaction [ Time Frame: Approximately 48-hours post-birth and 42+/-7 days postpartum ]
    Maternal satisfaction with study design and procedures, measured by a survey

  7. Healthcare provider satisfaction [ Time Frame: 18 months ]
    Healthcare provider satisfaction with study design and procedures, measured through a survey


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Capability of participant to comprehend and comply with study requirements
  • Age ≥18 years at time of consent
  • Nulliparous (never given birth after 19+6/7 weeks of gestation)
  • Pre-pregnancy BMI or calculated BMI obtained in the first 13 weeks of pregnancy ≥40kg/ m2
  • Participant plans to give birth in a participating site
  • Gestational age 34+0/7 - 36+6/7 weeks (based on estimated date of conception (EDC) assigned at the first ultrasound performed after 7+0/7 and prior to 20 +0/7 weeks)
  • Live fetus, documented positive heart rate at visit 1 prior to randomization
  • Singleton fetus in cephalic presentation at the time of randomization
  • No maternal or fetal contraindications to vaginal delivery

Exclusion Criteria:

  • Known major fetal anomaly, confirmed by ultrasound or genetic testing
  • Multiple gestation
  • Known documented evidence of alcohol or drug abuse in this current pregnancy
  • Currently enrolled or has participated in another clinical trial within 3 months of the date of randomization (at discretion of Trial Coordinating Centre)
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Alysha LJ Harvey, MSc 6137378899 ext 73838 alyharvey@ohri.ca
Contact: Rosemary Larose, RPN 6137378899 ext 75866 rlarose@ohri.ca

Locations
Layout table for location information
Canada, Ontario
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Contact: Alysha LJ Harvey, MSc    613-737-8899 ext 73838    alyharvey@ohri.ca   
Contact: Rosemary Larose, RPN    613-737-8899 ext 75866    rlarose@ohri.ca   
Principal Investigator: Laura M Gaudet, MD         
Sub-Investigator: Mark C Walker, MD         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Laura Gaudet, MD, MSc The Ottawa Hospital
Study Director: Ruth Rennicks White, BScN The Ottawa Hospital
Tracking Information
First Submitted Date  ICMJE May 21, 2019
First Posted Date  ICMJE June 14, 2019
Last Update Posted Date June 14, 2019
Estimated Study Start Date  ICMJE September 1, 2019
Estimated Primary Completion Date August 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
  • Feasibility of conducting a larger-scale trial (eligibility criteria) [ Time Frame: 18 months ]
    Appropriateness of eligibility criteria, measured by the reasons for exclusion of screened patients
  • Feasibility of conducting a larger-scale trial (recruitment rate) [ Time Frame: 18 months ]
    Eligibility and recruitment rate, measured by the proportion of patients who are eligible and recruited into the trial
  • Feasibility of conducting a larger-scale trial (randomization) [ Time Frame: 18 months ]
    Appropriateness of randomization, measured by the proportion of trial participants who consent to randomization
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
  • Maternal morbidity and mortality [ Time Frame: Pregnancy to 6 week postpartum ]
    Rates of: maternal death, admission to ICU, intrapartum Caesarean section, postpartum hemorrhage, postpartum wound infection, endometritis, venous thromboembolism (VTE), hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), indication for Caesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incision extensions during Caesarean section, chorioamnionitis, third or fourth degree perineal lacerations, induction agents, pain medication use during induction, labour, Caesarean section and postpartum.
  • Fetal and neonatal morbidity and mortality [ Time Frame: Pregnancy to 6 week postpartum ]
    Rates of: stillbirth, neonatal death, gestational age at birth, birthweight, need for respiratory support within 72 hours of birth, duration of respiratory support, 5 minute Apgar <7, hypoxic-ischemic encephalopathy, seizure, infection (confirmed sepsis or pneumonia), meconium aspiration syndrome, birth trauma (bone fracture, neurologic injury or retinal hemorrhage), cephalohematoma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support, breastfeeding rates, hypoglycemia requiring intravenous treatment, jaundice requiring treatment, need for transfusion.
  • Length of hospital stay [ Time Frame: Start of induction to delivery; admission to delivery; and delivery until discharge, assessed up until 6-weeks postpartum ]
    Length of hospital stay (in minutes) for both mom and baby
  • Hospital readmission rates [ Time Frame: Delivery to 6-weeks postpartum ]
    The proportion of mothers and/or infants re-admitted to the hospital
  • Techniques for induction of labour [ Time Frame: Admission to hospital until delivery, assessed up to 7 days from hospital admission. ]
    What method was used for induction
  • Maternal satisfaction [ Time Frame: Approximately 48-hours post-birth and 42+/-7 days postpartum ]
    Maternal satisfaction with study design and procedures, measured by a survey
  • Healthcare provider satisfaction [ Time Frame: 18 months ]
    Healthcare provider satisfaction with study design and procedures, measured through a survey
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity
Official Title  ICMJE The MODE Trial: A Pilot Trial Investigating Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity
Brief Summary

Canadian guidelines recommend that women with a pre-pregnancy body mass index (BMI) at or above 40 kg/m2 deliver by their due date. When delivery is planned prior to spontaneous labour, there are two options: planned induction of labour or pre-labour Caesarean (C-section). However, it is not yet clear whether induction of labour or planned pre-labour C-section is the best option for this population.

The MODE Trial aims to assess the feasibility of conducting a larger-scale trial of planned mode of delivery in first time mothers who have a BMI >=40kg/m2, and obtain preliminary data on health outcomes for moms and babies following delivery by either planned C-section or induction of labour.

Detailed Description

Women with obesity have a decreased likelihood of achieving vaginal delivery. According to the Centre for Maternal and Child Enquiries, the chance of spontaneous vaginal delivery in women with a BMI ≥35kg/m2 is 55%, while the chance is 36.7% in women with a BMI ≥40.0kg/m2. This number includes women who go into labour spontaneously, in which, the odds of a vaginal delivery are highest. The rate of failure to induce labour approaches 80% with increased complications and morbidity including abnormal fetal heart rate monitoring, labour dystocia, emergency C-section, and fetal macrosomia. It has been proposed that some women may benefit from a planned Caesarean section delivery. However, Caesarean sections are also not straightforward in women with obesity, and come with significant risks of short- and long-term morbidity for mother and baby, including prolonged operative times, higher volumes of blood loss and infection rates and higher rates of NICU admission.

Given that there are many considerations when deciding how to best deliver a woman with obesity, it is not surprising that there is a high degree of clinical equipoise. In reality, the decision is made jointly between the patient and her care provider, often guided by overall instinct and local resource availability.

Studies to date have been retrospective in nature. There is a significant need for prospective study of the outcomes and experiences of planned induction of labour and planned Caesarean section in women with obesity to allow evidence-based counselling and decision-making.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Brewin partially randomized control trial, patient preference trial. In this design, each eligible patient is asked for her preference for mode of delivery. Patients with a preference are given their delivery mode of choice. If a patient does not have a preference, randomization takes place. Advantages to this design include the fact that preferences are taken into account in care allocation and that almost all those who are eligible enter the study.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Obesity Complicating Childbirth
  • Obesity
  • Labor Onset and Length Abnormalities
  • Pregnancy, High Risk
  • Cesarean Section Complications
Intervention  ICMJE
  • Procedure: Caesarean section
    Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
    Other Names:
    • C-section
    • Cesarean
  • Procedure: Induction of Labour
    Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
Study Arms  ICMJE
  • Active Comparator: Randomized Caesarean section
    Randomized to planned pre-labour Caesarean section
    Intervention: Procedure: Caesarean section
  • Active Comparator: Randomized Induction of Labour
    Randomized to planned induction of labour
    Intervention: Procedure: Induction of Labour
  • Active Comparator: Preference Caesarean section
    Preference for planned pre-labour Caesarean section
    Intervention: Procedure: Caesarean section
  • Active Comparator: Preference Induction of Labour
    Preference for planned Induction of Labour
    Intervention: Procedure: Induction of Labour
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 12, 2019)
100
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 31, 2021
Estimated Primary Completion Date August 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Capability of participant to comprehend and comply with study requirements
  • Age ≥18 years at time of consent
  • Nulliparous (never given birth after 19+6/7 weeks of gestation)
  • Pre-pregnancy BMI or calculated BMI obtained in the first 13 weeks of pregnancy ≥40kg/ m2
  • Participant plans to give birth in a participating site
  • Gestational age 34+0/7 - 36+6/7 weeks (based on estimated date of conception (EDC) assigned at the first ultrasound performed after 7+0/7 and prior to 20 +0/7 weeks)
  • Live fetus, documented positive heart rate at visit 1 prior to randomization
  • Singleton fetus in cephalic presentation at the time of randomization
  • No maternal or fetal contraindications to vaginal delivery

Exclusion Criteria:

  • Known major fetal anomaly, confirmed by ultrasound or genetic testing
  • Multiple gestation
  • Known documented evidence of alcohol or drug abuse in this current pregnancy
  • Currently enrolled or has participated in another clinical trial within 3 months of the date of randomization (at discretion of Trial Coordinating Centre)
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Alysha LJ Harvey, MSc 6137378899 ext 73838 alyharvey@ohri.ca
Contact: Rosemary Larose, RPN 6137378899 ext 75866 rlarose@ohri.ca
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03985618
Other Study ID Numbers  ICMJE CRRF ID 1469
FDN148438 ( Other Grant/Funding Number: Canadian Institutes of Health Research )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Ottawa Hospital Research Institute
Study Sponsor  ICMJE Ottawa Hospital Research Institute
Collaborators  ICMJE Canadian Institutes of Health Research (CIHR)
Investigators  ICMJE
Principal Investigator: Laura Gaudet, MD, MSc The Ottawa Hospital
Study Director: Ruth Rennicks White, BScN The Ottawa Hospital
PRS Account Ottawa Hospital Research Institute
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP